Tamar Securities LLC Has $8.79 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tamar Securities LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 4.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,766 shares of the biopharmaceutical company’s stock after acquiring an additional 486 shares during the period. Regeneron Pharmaceuticals comprises approximately 2.8% of Tamar Securities LLC’s portfolio, making the stock its 12th biggest holding. Tamar Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $8,794,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Markel Corp boosted its holdings in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Markel Corp now owns 80,300 shares of the biopharmaceutical company’s stock valued at $56,083,000 after purchasing an additional 1,000 shares during the period. Cibc World Market Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Cibc World Market Inc. now owns 6,416 shares of the biopharmaceutical company’s stock worth $4,481,000 after acquiring an additional 86 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of Regeneron Pharmaceuticals by 18.4% during the first quarter. Blair William & Co. IL now owns 1,431 shares of the biopharmaceutical company’s stock worth $999,000 after purchasing an additional 222 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 23.1% during the 1st quarter. Sequoia Financial Advisors LLC now owns 495 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 93 shares during the last quarter. Finally, Baird Financial Group Inc. grew its stake in shares of Regeneron Pharmaceuticals by 100.9% during the first quarter. Baird Financial Group Inc. now owns 36,529 shares of the biopharmaceutical company’s stock valued at $25,513,000 after purchasing an additional 18,345 shares during the last quarter. Institutional investors own 84.25% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of several analyst reports. Cowen increased their target price on Regeneron Pharmaceuticals from $655.00 to $750.00 and gave the company a “market perform” rating in a research note on Thursday, October 20th. The Goldman Sachs Group boosted their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $970.00 and gave the stock a “buy” rating in a research report on Monday, October 3rd. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $868.00 to $873.00 and gave the stock an “overweight” rating in a research note on Tuesday. JPMorgan Chase & Co. raised shares of Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $850.00 target price on the stock in a report on Friday, January 20th. Finally, Truist Financial lifted their price objective on shares of Regeneron Pharmaceuticals from $790.00 to $856.00 in a research report on Wednesday, November 9th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $786.15.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director N Anthony Coles sold 5,758 shares of the stock in a transaction on Wednesday, December 28th. The stock was sold at an average price of $714.11, for a total value of $4,111,845.38. Following the sale, the director now owns 1,093 shares in the company, valued at $780,522.23. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director N Anthony Coles sold 5,758 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, December 28th. The stock was sold at an average price of $714.11, for a total value of $4,111,845.38. Following the transaction, the director now directly owns 1,093 shares in the company, valued at approximately $780,522.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 4th. The stock was sold at an average price of $727.82, for a total transaction of $727,820.00. Following the transaction, the executive vice president now owns 19,644 shares of the company’s stock, valued at approximately $14,297,296.08. The disclosure for this sale can be found here. Over the last quarter, insiders sold 19,212 shares of company stock worth $14,070,511. Corporate insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

REGN traded up $9.67 during midday trading on Wednesday, hitting $737.14. 107,498 shares of the company traded hands, compared to its average volume of 616,375. Regeneron Pharmaceuticals, Inc. has a 52 week low of $538.01 and a 52 week high of $779.00. The company has a quick ratio of 4.52, a current ratio of 5.36 and a debt-to-equity ratio of 0.13. The company’s 50-day moving average is $732.22 and its 200 day moving average is $690.27. The firm has a market capitalization of $80.28 billion, a PE ratio of 15.34, a price-to-earnings-growth ratio of 2.17 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last announced its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported $9.98 EPS for the quarter, beating the consensus estimate of $8.55 by $1.43. Regeneron Pharmaceuticals had a net margin of 39.17% and a return on equity of 31.16%. The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.79 billion. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 38.45 EPS for the current year.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.